U.S. Markets closed

KemPharm Stock Breaks Out on Clinical Trial Results

Justin Kuepper

KemPharm, Inc. ( KMPH) shares rose more than 10% by Friday afternoon after the company reported positive top-line results from the first of three pivotal human abuse clinical trials for KP415. The prodrug of d-methylphenidate for the treatment of attention deficit and hyperactivity disorder (ADHD) is designed to lower potential abuse compared with stimulant-based ADHD products, which could make it a go-to prescription within the multi-billion-dollar industry. In the clinical trial, researchers found that the prodrug was not readily converted into the active d-methylphenidate when injected, and as a result, it produced pharmacodynamic effects that were comparable to placebo endpoints.